Phase II study to evaluate the safety and efficacy of subcutaneous bioresorbable afamelanotide 16 mg implants in patients with Hailey-Hailey Disease (HHD).
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Afamelanotide (Primary)
- Indications Pemphigus
- Focus Therapeutic Use
- 10 Feb 2014 Status changed from planning to recruiting, as reported by a Clinuvel Pharmaceuticals media release.
- 02 Dec 2013 New trial record